Bad visual outcome linked to clinical signs of AMD at time of cataract surgery

Article

Patients presenting with age-related macula degeneration (AMD) signs at cataract surgery have a longitudinally worse visual outcome compared to patients without AMD signs.

Patients presenting with age-related macula degeneration (AMD) signs at cataract surgery have a longitudinally worse visual outcome compared to patients without AMD signs, states a study in the Journal of Cataract and Refractive Surgery.

The longitudinal cohort study, led by Dr Eva Monestam, Department of Clinical Sciences and Ophthalmology, Faculty of Medicine, Norrlands University Hospital, Umeå University, Sweden, evaluated 810 patients.

Corrected distance visual acuity (CDVA) and clinical eye examinations were performed before and after surgery and 5 and 10 years after surgery for eligible patients. All participants were split into functional groups determined by postoperative signs of AMD and CDVA.

In AMD patients the rate of CDVA decline with age was faster compared to patients without comorbidity. In groups where CDVA was almost normal or reduced the slope of the visual acuity decline was similar.

In patients with no comorbidity there was a mean loss of 2.3 logMAR letters and 6.4 letters in AMD patients for each decade of increasing age. Better CDVA was seen in 75% of AMD patients 10 years postoperatively.

As a result of this, the study authors recommend that AMD patients are not discouraged from undergoing cataract surgery.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.